Risk of venous thromboembolism in patients with chronic liver disease and the utility of venous thromboembolism prophylaxis;Le risque de thromboembolies veineuses (TEV) chez les patients avec maladie hépatique chronique et l'utilité de la prophylaxie pour la thromboembolie veineuse

Annals of Pharmacotherapy

Volumn 46, Issue 6, 2012, Pages 873-878

  Pincus, Kathleen J ^a   Tata, Asha L ^b   Watson, Kristin ^c  

^a UNIVERSITY OF MARYLAND SCHOOL OF PHARMACY   (United States)

^b UNIVERSITY OF MARYLAND MEDICAL CENTER   (United States)

^c UNIVERSITY OF MARYLAND   (United States)

Author keywords

Anticoagulation; Liver disease; Venous thromboembolism

Indexed keywords

ANTICOAGULANT AGENT; ANTITHROMBIN III; PHOSPHOLIPID ANTIBODY; SERUM ALBUMIN;

ANTICOAGULATION; ARTICLE; CARDIOVASCULAR RISK; CHRONIC LIVER DISEASE; DIABETES MELLITUS; DRUG INDICATION; HUMAN; INTERNATIONAL NORMALIZED RATIO; OBSERVATIONAL STUDY; PRIORITY JOURNAL; PROPHYLAXIS; PROTEIN C DEFICIENCY; PROTEIN S DEFICIENCY; RETROSPECTIVE STUDY; RISK ASSESSMENT; SYSTEMATIC REVIEW; VENOUS THROMBOEMBOLISM;

ANTICOAGULANTS; HOSPITALIZATION; HUMANS; LIVER DISEASES; RISK; VENOUS THROMBOEMBOLISM;

EID: 84862250324     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1Q726     Document Type: Article

References (25)

1. Jaffer AK, Amin AN, Brotman DJ, Deitelzweig SB, McKean SC, Spyropoulos AC. Prevention of venous thromboembolism in the hospitalized medical patient. Cleve Clin J Med 2008;75:S7-S16.
2. Khoury H, Welner S, Kubin M, Folkerts K, Haas S. Disease burden and unmet needs for prevention of venous thromboembolism in medically ill patients in Europe show underutilization of preventive therapies. Thromb Haemost 2011;106:600-8.
3. Mahan CE, Holdsworth MT, Welch SM, Borrego M, Spyropoulos AC. Deep-vein thrombosis: a United States cost model for a preventable and costly adverse event. Thromb Haemost 2011;106:405-15.
4. Kahn SR, Lim W, Dunn AS, et al. Prevention of VTE in nonsurgical patients: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012;141:e195s-e226s.
5. Qaseem A, Chou R, Humphrey LL, Sarkey M, Shekelle P. Venous thromboembolism prophylaxis in hospitalized patients: a clinical practice guideline from the American College of Physicians. Ann Intern Med 2011;155:625-32.
6. Kakkar AK, Cimminiello C, Goldhaber SZ, et al. Low-molecular-weight heparin and mortality in acutely ill medical patients. N Engl J Med 2011; 365:2463-72.
7. Lisman T, Porte RJ. Rebalanced hemostasis in patients with liver disease: evidence and clinical consequences. Blood 2010;116:878-85.
8. Tripodi A, Mannucci PM. The coagulopathy of chronic liver disease. N Engl J Med 2011;365:147-56.
9. Terjung B, Lemnitzer I, Dumoulin FL, et al. Bleeding complications after percutaneous liver biopsy: an analysis of risk factors. Digestion 2003;67: 138-45.
10. Massicotte L, Beaulieu D, Roy JD. MELD score and blood product requirements during liver transplantation: no link. Transplantation 2009; 87:1689-94.
11. Segal JB, Dzik WH. Paucity of studies to support that abnormal coagulation test results predict bleeding in the setting of invasive procedures: an evidence-based review. Transfusion 2005;45:1413-25.
12. Heit JA, Silverstein MD, Mohr DN, Petterson TM, O'Fallon WM, Melton J. Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study. Arch Intern Med 2000; 160:809-15.
13. Heurta C, Johansson S, Wallander MA, Garcia Rodriguez LA. Risk factors and short-term mortality of venous thromboembolism diagnosed in the primary care setting in the United Kingdom. Arch Intern Med 2007; 167:935-43.
14. Northrup PG, McMahon MM, Parker Ruhl A, et al. Coagulopathy does not fully protect hospitalized cirrhosis patients from peripheral venous thromboembolism. Am J Gastroenterol 2006;101:1524-8.
15. Garcia-Fuster MJ, Abdilla N, Fabia MJ, Fernandez C, Oliver V, Fomer MJ. Venous thromboembolism and liver cirrhosis. Rev Esp Enferm Dig 2008;100:259-62.
16. Lesmana CRA, Inggriani S, Cahyadinata L, Lesmana LA. Deep vein thrombosis in patients with advanced liver cirrhosis: a rare condition? Hepatol Int 2010;4:433-8.
17. Aldawood A, Arabi Y, Aljumah A, et al. The incidence of venous thromboembolism and practice of deep venous thrombosis prophylaxis in hospitalized cirrhotic patients. Thromb J 2011;9:1-6.
18. Gulley D, Teal E, Suvannasankha A, Chalasani N, Liangpunsakul S. Deep vein thrombosis and pulmonary embolism in cirrhosis patients. Dig Dis Sci 2008;53:3012-7.
19. Dabbagh O, Oza A, Prakash S, Sunna R, Saettele TM. Coagulopathy does not protect against venous thromboembolism in hospitalized patients with chronic liver disease. Chest 2010;137:1145-9.
20. Sogaard KK, Horvath-Puho E, Gronbaek H, Jepsen P, Vilstrup H, Sorensen HT. Risk of venous thromboembolism in patients with liver disease: a nationwide population-based case-control study. Am J Gastroenterol 2009;104:96-101.
21. Wu H, Nguyen GC. Liver cirrhosis is associated with venous thromboembolism among hospitalized patients in a nationwide US study. Clin Gastroenterol Hepatol 2010;8:800-5.
22. Cohen AT, Tapson VF, Bergmann JF, et al. Venous thromboembolism risk and prophylaxis in the acute hospital care setting (ENDORSE study): a multinational cross-sectional study. Lancet 2008;371:387-94.
23. Bechmann LP, Sichau M, Wichert M, Gerken G, Kroger K, Hilgard P. Low-molecular-weight heparin in patients with advanced cirrhosis. Liver Int 2011;31:75-82.
24. Northrup PG, Intagliata NM. Anticoagulation in cirrhosis patients: what don't we know? Liver Int 2011;31:4-6.
25. Goodman SG, Cohen M, Bigonzi F, et al. Randomized trial of low molecular weight heparin (enoxaparin) versus unfractionated heparin for unstable coronary artery disease: one-year results of the ESSENCE Study. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q Wave Coronary Events. J Am Coll Cardiol 2000;36:693-8.